New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma

Journal of Clinical Oncology

Volumn 33, Issue 11, 2015, Pages e52-e56

  Carlino, Matteo S ^a   Kwan, Vu ^b   Miller, David K ^c   Saunders, Catherine A B ^b   Yip, Desmond ^d   Nagrial, Adnan M ^e   Tomlinson, Jeanne ^b   Grimmond, Sean M ^c   Scolyer, Richard A ^f   Kefford, Richard F ^a   Biankin, Andrew V ^e,g,h   Long, Georgina V ⁱ  

^a WESTMEAD HOSPITAL   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d CANBERRA HOSPITAL   (Australia)

^e GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^f ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^g UNIVERSITY OF NEW SOUTH WALES   (Australia)

^h UNIVERSITY OF GLASGOW   (United Kingdom)

ⁱ UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DABRAFENIB; FLUORODEOXYGLUCOSE F 18; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN S100B; RAS PROTEIN; TRAMETINIB; TUMOR ANTIGEN; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; KRAS PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; ONCOPROTEIN; OXIME; PROTEIN KINASE INHIBITOR; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE;

ADULT; AXILLARY LYMPHADENOPATHY; BILIARY STENT; BONE METASTASIS; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CUTANEOUS MELANOMA; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENDOSCOPIC ULTRASOUND GUIDED FINE NEEDLE BIOPSY; ENZYME INHIBITION; EXCISION; EXON; HUMAN; HUMAN TISSUE; LIVER METASTATIC MELANOMA; LYMPH NODE BIOPSY; LYMPH NODE MELANOMA; LYMPHADENOPATHY; MALE; MELANOMA; METASTATIC MELANOMA; MIDDLE AGED; NOTE; OBSTRUCTIVE JAUNDICE; ONCOGENE RAS; PANCREAS ADENOCARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SYSTEMIC THERAPY; UNSPECIFIED SIDE EFFECT; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; BIOPSY; CHEMICALLY INDUCED; COMPUTER ASSISTED TOMOGRAPHY; ENZYMOLOGY; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MOLECULARLY TARGETED THERAPY; MUTATION; NUCLEOTIDE SEQUENCE; PANCREATIC NEOPLASMS; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; RISK FACTOR; SECONDARY; SKIN NEOPLASMS; TIME; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; DNA MUTATIONAL ANALYSIS; HUMANS; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; MALE; MAP KINASE KINASE KINASES; MELANOMA; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; OXIMES; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDONES; PYRIMIDINONES; RAS PROTEINS; RISK FACTORS; SKIN NEOPLASMS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84927553846     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.51.5783     Document Type: Note

References (18)

1. Flaherty KT, Infante JR, Daud A, et al: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367:1694-1703, 2012
2. Callahan MK, Rampal R, Harding JJ, et al: Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med 367:2316-2321, 2012
3. Chapman P, Metz D, Sepulveda AR, et al: Development of colonic adenomas and gastric polyps in BRAF mutant melanoma patients treated with vemurafenib. Society for Melanoma Research Congress, Los Angeles, CA, November 8-11, 2012
4. Zimmer L, Hillen U, Livingstone E, et al: Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol 30:2375-2383, 2012
5. Eisenhauer EA, Therasse P, Boggaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
6. illumina: TruSeq Amplicon-Cancer Panel http://www.illumina.com/ products/truseq-amplicon-cancer-panel.ilmn
7. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516, 2011
8. Flaherty KT, Robert C, Hersey P, et al: Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367:107-114, 2012
9. Anforth R, Fernandez-Peñas P, Long GV: Cutaneous toxicities of RAF inhibitors. Lancet Oncol 14:e11-e18, 2013
10. Su F, Viros A, Milagre C, et al: RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 366:207-215, 2012
11. Poulikakos PI, Zhang C, Bollag G, et al: RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464:427-430, 2010
12. Heidorn SJ, Milagre C, Whittaker S, et al: Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140:209-221, 2010
13. Hatzivassiliou G, Song K, Yen I, et al: RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464:431-435, 2010
14. Dalle S, Poulalhon N, Thomas L: Vemurafenib in melanoma with BRAF V600E mutation, N Engl J Med 365:1448-1449, 2011
15. Lipowicz S, Chagnon S, Saiag P: Rapidly growing pancreatic ductal adenocarcinoma in a patient with metastatic melanoma and harbouring CDKN2A germline mutation. Melanoma Res 23:241, 2013
16. Infante JR, Fecher LA, Falchook GS, et al: Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: A phase 1 dose-escalation trial. Lancet Oncol, 13:773-781, 2012
17. Andrews MC, Behren A, Chionh F, et al: BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition. J Clin Oncol 31:e448-e451, 2013
18. Balch CM, Gershenwald JE, Soong Sj, et al: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199-6206, 2009